Gastric / GEJ adenocarcinoma · Bismuth quadruple therapy (PBMT) — 14 days

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-HP-BISMUTH-QUADRUPLE`

ID	`IND-H-PYLORI-PREVENTION-ERADICATION`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-GASTRIC`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — v0.2-A continuation. Two-Co-Lead signoff queued. Eradication regimen (REG-HP-BISMUTH-QUADRUPLE or REG-HP-PPI-CLAR-AMOX or REG-HP-VONOPRAZAN-AMOX) needs separate authoring with new Drug entities (clarithromycin, amoxicillin, omeprazole/vonoprazan, bismuth subcitrate, tetracycline). Indication currently authored with recommended_regimen=null and regimen options in rationale; future commit replaces with proper Regimen FK once those entities land. Sources TODO: IARC Monograph 100B (H. pylori Group 1), Maastricht VI / Florence Consensus 2022, AGA 2024 H. pylori treatment guideline as new SRC-* entities.

Used By

Contraindications

CI-BISMUTH-RENAL-FAILURE - CI-BISMUTH-RENAL-FAILURE

Indication

IND-H-PYLORI-PREVENTION-OBSERVATION - IND-H-PYLORI-PREVENTION-OBSERVATION

Red flag

RF-CHRONIC-H-PYLORI-MALIGNANCY-PREVENTION - Chronic Helicobacter pylori infection (positive urea breath test, stool antigen, gastric...